Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ClinicalTrials.Gov: Confidentiality Concerns Are Decreasing, PhRMA Says

Executive Summary

Pharmaceutical manufacturers are becoming more comfortable with the disclosures required on ClinicalTrials.gov as they become more familiar with the system, Pharmaceutical Research & Manufacturers of America Associate VP-Regulatory Affairs Alan Goldhammer, PhD, reports
Advertisement

Related Content

ClinicalTrials.gov Postings By Industry Increase, But Still Appear Incomplete
ClinicalTrials.gov Postings By Industry Increase, But Still Appear Incomplete
FDA Launches Phase IV Tracking System; Baseline Is 20% Completion Rate
FDA Launches Phase IV Tracking System; Baseline Is 20% Completion Rate
ClinicalTrials.Gov Lists 22 Lilly Studies; Response To FDA Deadline Is Mixed
FDA Sets 45-Day Deadline For Listing Studies In ClinicalTrials.Gov
FDA Sets 45-Day Deadline For Listing Studies In ClinicalTrials.Gov
Advertisement
UsernamePublicRestriction

Register

PS040258

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel